Products - Infection - Tuberculosis

Tuberculosis

Contact our Infectious Disease Product Team for further details and information

Information

Tuberculosis, or TB, is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB). Microscopic droplets suspended in the air pass the TB organism from person to person. Infection can occur when an uninfected person comes in contact with someone who has active tuberculosis.

Two methods exist to aid in detection of latent TB – an intradermal injection known as the tuberculin skin test (TST) or blood-based tests referred to as interferon-gamma release assays (IGRAs) – with other clinical findings and risk assessment.

Tuberculosis products

For in vitro diagnostic use. Refer to the instructions for use for more information.

The T-SPOTâ„¢.TB test from Revvity is an IGRA designed to enable accurate results across patient populations, even in patients with a weakened immune status1. This unique, single visit, single tube blood test reduces assay variability and maximizes sensitivity by separating T cells from whole blood and standardizing the number of these cells in each test well. The T-Cell Selectâ„¢ reagent kit enables the automation of cell isolation and removes potentially interfering substances that can affect test results.1 This test design mitigates the risk of false or invalid results.

In the United States, the T-SPOT.TB test is commercially supported by EUROIMMUN US. For more information, please contact us or visit tspot.com.

ELISPOT methodology

The immune response to infection with MTB is mediated predominantly through T cell activation. As part of this response, T cells are sensitized to MTB antigens and the activated effector T cells, both CD4+ and CD8+, produce the cytokine interferon-gamma when stimulated by these antigens. The T-SPOT.TB test uses the enzyme-linked immunospot (ELISPOT) methodology to enumerate MTB-sensitized T cells by capturing interferon-gamma in the vicinity of T cells from which it was secreted.

The T-SPOT.TB test is approved by the United States Food and Drug Administration (FDA) for patients two and older, including BCG-vaccinated patients, healthy patients, and patients with compromised immune systems.1

wdt_ID Method Parameter Substrate Species/ Antigen
600 ELISPOT Antibodies against MTB antigens Antigen coated microplate wells
601 Cell Isolation Peripheral blood mononuclear cells (PBMCs) Reagent kit
Method Parameter Substrate Species/ Antigen

1. Oxford Immunotec. T-SPOT.TB Package Insert TB-PI-US-0001 V13. Abingdon, UK. November 2023.

T-SPOT and T-Cell Select are trademarks of Oxford Immunotec Ltd.
Contact our Infectious Disease Product Team for further details and information
Download Our Latest <br/>EUROIMMUN US Product Catalog

Product Catalog

Download Our Latest
EUROIMMUN US Product Catalog

Download The EUROIMMUN US Product Catalog (PDF)

2024 EUROIMMUN US

Privacy Policy | Website Terms and Conditions | Cookie Notice and Settings | Consent Preferences | Sitemap